Abstract:The discovery of novel therapeutic compounds through de novo drug design represents a critical challenge in the field of pharmaceutical research. Traditional drug discovery approaches are often resource intensive and time consuming, leading researchers to explore innovative methods that harness the power of deep learning and reinforcement learning techniques. Here, we introduce a novel drug design approach called drugAI that leverages the Encoder–Decoder Transformer architecture in tandem with Reinforcement Learning via a Monte Carlo Tree Search (RL-MCTS) to expedite the process of drug discovery while ensuring the production of valid small molecules with drug-like characteristics and strong binding affinities towards their targets. We successfully integrated the Encoder–Decoder Transformer architecture, which generates molecular structures (drugs) from scratch with the RL-MCTS, serving as a reinforcement learning framework. The RL-MCTS combines the exploitation and exploration capabilities of a Monte Carlo Tree Search with the machine translation of a transformer-based Encoder–Decoder model. This dynamic approach allows the model to iteratively refine its drug candidate generation process, ensuring that the generated molecules adhere to essential physicochemical and biological constraints and effectively bind to their targets. The results from drugAI showcase the effectiveness of the proposed approach across various benchmark datasets, demonstrating a significant improvement in both the validity and drug-likeness of the generated compounds, compared to two existing benchmark methods. Moreover, drugAI ensures that the generated molecules exhibit strong binding affinities to their respective targets. In summary, this research highlights the real-world applications of drugAI in drug discovery pipelines, potentially accelerating the identification of promising drug candidates for a wide range of diseases.

Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models

Nc-vae: normalised conditional diverse variational autoencoder guided de novo molecule generation

Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks

Comprehensive assessment of deep generative architectures for de novo drug design

Molecular design in drug discovery: a comprehensive review of deep generative models

Balancing Exploration and Exploitation: Disentangled $β$-CVAE in De Novo Drug Design

Generative chemistry: drug discovery with deep learning generative models

Deep generative models in the quest for anticancer drugs: ways forward

Status and Prospects of Research on Deep Learning-based De Novo Generation of Drug Molecules

Advances in De Novo Drug Design: From Conventional to Machine Learning Methods

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search

Shape-Based Generative Modeling for de Novo Drug Design

Recent advances and application of generative adversarial networks in drug discovery, development, and targeting

A Transformer-based Generative Model for De Novo Molecular Design

Structure-Based Drug Design with a Deep Hierarchical Generative Model

Deep Generative Models in De Novo Drug Molecule Generation

ScaffoldGVAE: scaffold generation and hopping of drug molecules via a variational autoencoder based on multi-view graph neural networks

Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design

Unlocking the potential of generative AI in drug discovery

Deep learning approaches for <i>de novo</i> drug design: An overview

Advances and Challenges in De Novo Drug Design Using Three-Dimensional Deep Generative Models